SequelSEC

Arcadia Biosciences, Inc. RKDA

Crude Petroleum & Natural Gas · CIK 0001469443 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.44M
Fiscal year ended 2026-06-30
Operating income
-$496.00K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$5.74MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.79Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Crude Petroleum & Natural Gas filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%0th
Current ratio3.09x89th
SBC / revenue4.8%83th
Operating margin-51.5%17th
Net margin-48.1%18th
Gross margin36.2%26th
Revenue YoY growth-3.7%40th

Arcadia Biosciences, Inc. (RKDA) reported revenue of $1.44M and net income of -$6.27M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Arcadia Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Crude Petroleum & Natural Gas.

Income

Arcadia Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$1.44M$1.10M$901.00K$1.30M$1.46M$1.20M$1.22M$1.54M$1.31M$987.00K
Cost of revenue$812.00K$700.00K$709.00K$884.00K$824.00K$682.00K$827.00K$1.03M$633.00K$471.00K
Gross profit$631.00K$400.00K$192.00K$418.00K$631.00K$518.00K$389.00K$505.00K$673.00K$516.00K
Operating income-$496.00K-$779.00K-$1.38M-$1.15M-$501.00K$530.00K-$2.28M-$1.76M$1.98M-$1.59M
Net income-$6.27M-$4.38M-$1.34M$856.00K-$4.46M$2.60M-$4.06M-$1.61M$1.06M-$2.42M
Research & development$0Unavailable$0$0$9.00K$0$13.00K$24.00K$10.00K$6.00K
Weighted-average diluted sharesshares 2.99Mshares 2.08MUnavailableshares 1.37Mshares 1.37Mshares 1.37MUnavailableshares 1.36Mshares 1.36Mshares 1.36M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$4.03M-$1.18M$1.85MUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$8.00K$0$0Unavailable
Diluted EPS$-2.09$-2.11Unavailable$0.62$-3.26$1.90Unavailable$-1.18$0.78$-1.78
Selling, general & administrative$1.13M$1.18M$1.57M$1.57M$2.12M$1.74M$2.66M$2.24M$2.68M$2.06M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Arcadia Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$4.18M$954.00K$259.00K$1.12M$1.38M$3.16M$4.24M$3.94M$5.50M$3.32M
Total assets$5.89M$5.32M$6.55M$8.58M$7.79M$12.99M$13.52M$15.24M$17.37M$16.05M
Current assets$5.74M$5.17M$6.36M$8.39M$7.58M$8.85M$9.24M$10.71M$12.43M$11.64M
Total liabilities$5.26M$2.44M$2.41M$3.14M$3.26M$4.08M$7.29M$5.09M$5.80M$5.56M
Current liabilities$1.65M$1.36M$2.06M$2.28M$1.84M$2.22M$2.56M$2.33M$2.70M$2.88M
Total equity incl. NCI$633.00K$2.88M$4.14M$5.44M$4.53M$8.90M$6.22M$10.15M$11.57M$10.48M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$930.00K$840.00K$1.21M$1.46M$1.49M$1.28M$904.00K$835.00K$978.00K$1.83M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Arcadia Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$319.00K-$1.10M-$822.00K-$257.00K-$2.03M-$1.59M-$2.21M-$1.75M-$2.46M-$3.21M
Capital expendituresUnavailableUnavailable$0$0$0$0$0$0$3.00K$13.00K
Investing cash flow$0$0$0$0$250.00K$500.00K$2.52M$180.00K$4.64M$4.00K
Financing cash flow$3.54M$1.79M$0$1.00K$0$5.00K$0$4.00K$0$5.00K
Net change in cash$3.22M$695.00K-$861.00K-$256.00K-$1.78M-$1.08M$306.00K-$1.57M$2.19M-$3.20M
Stock-based compensation$14.00K$15.00K$17.00K$53.00K$86.00K$78.00K$117.00K$155.00K$102.00K$138.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Arcadia Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailable-$257.00KUnavailableUnavailable-$2.21M-$1.75M-$2.46M-$3.22M
Gross margin43.7%36.4%21.3%32.1%43.4%43.2%32.0%32.9%51.5%52.3%
Operating margin-34.4%-70.8%-152.6%-88.5%-34.4%44.2%-187.4%-114.5%151.6%-160.9%
FCF marginUnavailableUnavailableUnavailable-19.7%UnavailableUnavailable-181.7%-114.0%-188.3%-326.5%
SBC / revenue1.0%1.4%1.9%4.1%5.9%6.5%9.6%10.1%7.8%14.0%
Current ratio3.49x3.79x3.09x3.67x4.12x3.99x3.61x4.60x4.61x4.05x
Revenue YoY growth-0.8%-8.3%-25.9%-15.3%11.4%21.6%56.5%18.4%0.7%-19.9%
Net margin-434.2%-398.6%-148.3%65.7%-306.4%216.6%-334.2%-104.9%81.2%-245.5%
R&D / revenue0.0%Unavailable0.0%0.0%0.6%Unavailable1.1%1.6%0.8%0.6%
CapEx / revenueUnavailableUnavailable0.0%0.0%UnavailableUnavailable0.0%0.0%0.2%1.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RKDA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K/A · Filed 2026-04-30View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.